Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics

Frontiers in Microbiology

Microbiology

Ruojun Wang¹ 

[1] null;

关键词: Clostridioides difficile;    Clostridioides difficile;    gut microbiota;    microbe-microbe interactions;    live biotherapeutic products (LBP);    fecal microbiota transplantation (FMT);   

DOI  :  10.3389/fmicb.2023.1182612

 received in 2023-03-09, accepted in 2023-04-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

Clostridioides difficile is a gram-positive, spore-forming, obligate anaerobe that infects the colon. C. difficile is estimated to cause nearly half a million cases in the United States annually,withabout 29,000 associated deaths. Unfortunately, the current antibiotic treatment is not ideal. While antibiotics can treat the infections, they also disrupt the gut microbiota that mediates colonization resistance against enteric pathogens, including C. difficile; disrupted gut microbiota provides a window of opportunity for recurrent infections. Therefore, therapeutics that restore the gut microbiota and suppress C. difficile are being evaluated for safety and efficacy. This review will start with mechanisms by which gut bacteria affect C. difficile pathogenesis, followed by a discussion on biotherapeutics for recurrent C. difficile infections.

【 授权许可】

Unknown   
Copyright © 2023 Wang.